干细胞领域知识发现平台

提升科研信息化水平
支撑研究所科技创新

  融合多源信息    打通数据孤岛
  挖掘知识关联    放大数据价值
  集成知识计算    促进知识发现

免费注册账号
查看全文和研发动态、知识导航以及收藏您喜欢的数据等操作,您需要注册一个免费帐户并登录。

写笔记

您最近的笔记
Drug Name:BBI-801
Regulatory Designations:     
Originator Company: Boston Biomedical Inc Active Companies: Boston Biomedical Inc
Last Change Date: 2018-03-28

extract

Boston Biomedical is investigating BBI-801, a gene silencing agent developed using the proprietary asymmetrical interfering RNA (aiRNA) technology from AiRNA Pharmaceuticals and Boston Biomedical, which inhibits cancer cell stemness pathways and promotes anti-cancer immunity through targeting beta-catenin and PD-L1, for the potential treatment of cancer [ 1697726 ], [ 1907364 ]. In September 2015, the drug was in preclinical development [ 1697726 ]. In March 2017, preclinical studies were ongoing


Other Drug Names:

BBI-801; PD-L1 checkpoint inhibitor (cancer), Boston Biomedical; aRNAi therapeutics (cancer), Boston Biomedical; beta-catenin/PD-L1 dual modulators (aiRNA technology, cancer), Boston Biomedical; stem cell pathway modulators (aiRNA technology, cancer), Boston Biomedical

Technologies

Biological therapeutic; Immuno-oncology; Parenteral formulation unspecified; RNA antisense

Development Status (Current)

Boston Biomedical Inc: US: Discovery: Cancer: 25-Sep-2015

Development Status (History)


Drug Development Phase

[Cancer: Discovery: US]

Therapy Area:

Cancer


Highest Status

Discovery


Target-based Actions

CTNNB1 gene inhibitor; PDCD1L1 gene inhibitor


Other Actions

Anticancer; Immunostimulant; T-lymphocyte stimulator


Active Indications

Cancer